You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》富瑞降藥明生物(02269.HK)目標價至69元 觀察公司基本面仍強勁
阿思達克 12-05 10:28
富瑞發表報告指,藥明生物(02269.HK)下調今年銷售增長預測至12%,並降經調整純利預測至按年錄單位數跌幅,受累生物科技資金渠道轉弱及CMO項目押後;公司並降明年指引,料明年銷售及經調整純利各錄雙位數增長;並料2025年銷售及經調整純利各錄30%增長。 該行指,鑑於藥明生物僅能在明年下半年重拾增長趨勢,加上2024年是美國大選年,令其股價較其他生物製造同業更加敏感,該行認為,投資者只會願意在明年下半年購入藥明生物,並於2025年進行定位,同時期待大選後對中美的關注逐漸消失。 該行表示,觀察到公司基本面仍強勁,將其目標價由90元下調至69元,維持其評級為「買入」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account